Molecular, pharmacological and functional diversity of 5-HT receptors
暂无分享,去创建一个
[1] J. Sutcliffe,et al. The 5‐HT5A serotonin receptor is expressed predominantly by astrocytes in which it inhibits cAMP accumulation: A mechanism for neuronal suppression of reactive astrocytes , 1996, Glia.
[2] M. Millan,et al. Discriminative stimulus properties of the novel serotonin (5-HT)2C receptor agonist, RO60-0175: a pharmacological analysis , 1999, Neuropharmacology.
[3] R. Eglen,et al. RS-102221: A Novel High Affinity and Selective, 5-HT2C Receptor Antagonist , 1997, Neuropharmacology.
[4] J. Fozard,et al. The 5-HT4 receptor: a place in the sun. , 1992, Trends in pharmacological sciences.
[5] S. Ross,et al. Different effects on the responses of functional pre- and postsynaptic 5-HT1A receptors by repeated treatment of rats with the 5-HT1A receptor agonist 8-OH-DPAT , 1990, Neuropharmacology.
[6] D. Middlemiss,et al. L‐694,247: a potent 5‐HT1D receptor agonist , 1993, British journal of pharmacology.
[7] R Hen,et al. Human 5-HT(5) receptors: the 5-HT(5A) receptor is functional but the 5-HT(5B) receptor was lost during mammalian evolution. , 2001, European journal of pharmacology.
[8] John A. Peters,et al. The 5-HT3B subunit is a major determinant of serotonin-receptor function , 1999, Nature.
[9] C. Marsden,et al. Pindolol‐insensitive [3H]‐5‐hydroxytryptamine binding in the rat hypothalamus; identity with 5‐hydroxytryptamine7 receptors , 1999, British journal of pharmacology.
[10] K. Buchheit,et al. The serotonin 5-HT4 receptor. 2. Structure-activity studies of the indole carbazimidamide class of agonists. , 1995, Journal of medicinal chemistry.
[11] G. H. Dreteler,et al. Systemic and Regional Hemodynamic Effects of the 5‐Hydroxytryptamine1A Receptor Agonists Flesinoxan and 8‐Hydroxy-2(Di-N-Propylamino)Tetralin in the Conscious Rat , 1991, Journal of Cardiovascular Pharmacology.
[12] A. Sleight,et al. Characterization of Ro 04‐6790 and Ro 63‐0563: potent and selective antagonists at human and rat 5‐HT6 receptors , 1998, British journal of pharmacology.
[13] D. Middlemiss,et al. Importance of h5-HT1B Receptor Selectivity for 5-HT Terminal Autoreceptor Activity: an In Vivo Microdialysis Study in the Freely-moving Guinea-pig , 1997, Neuropharmacology.
[14] T. Branchek,et al. 5-ht6 receptors as emerging targets for drug discovery. , 2000, Annual review of pharmacology and toxicology.
[15] M. Jurzak,et al. Human 5-hydroxytryptamine(5A) receptors activate coexpressed G(i) and G(o) proteins in Spodoptera frugiperda 9 cells. , 2000, Molecular pharmacology.
[16] D. Boger,et al. Exceptionally potent inhibitors of fatty acid amide hydrolase: the enzyme responsible for degradation of endogenous oleamide and anandamide. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[17] M. Mattei,et al. Mouse 5-hydroxytryptamine5A and 5-hydroxytryptamine5B receptors define a new family of serotonin receptors: cloning, functional expression, and chromosomal localization. , 1993, Molecular pharmacology.
[18] M. Erlander,et al. A novel adenylyl cyclase-activating serotonin receptor (5-HT7) implicated in the regulation of mammalian circadian rhythms , 1993, Neuron.
[19] M. Camilleri. Review article: tegaserod. , 2001, Alimentary pharmacology & therapeutics.
[20] A. Brown,et al. 5-Chloro-N-(4-methoxy-3-piperazin-1-yl- phenyl)-3-methyl-2-benzothiophenesulfon- amide (SB-271046): a potent, selective, and orally bioavailable 5-HT6 receptor antagonist. , 1999, Journal of medicinal chemistry.
[21] M. Millan,et al. 5-HT1A receptors and the tail-flick response. IV. Spinally localized 5-HT1A receptors postsynaptic to serotoninergic neurones mediate spontaneous tail-flicks in the rat. , 1993, The Journal of pharmacology and experimental therapeutics.
[22] R M Eglen,et al. RS‐127445: a selective, high affinity, orally bioavailable 5‐HT2B receptor antagonist , 1999, British journal of pharmacology.
[23] E. Kirkness,et al. Evidence for Expression of Heteromeric Serotonin 5‐HT3 Receptors in Rodents , 2000, Journal of neurochemistry.
[24] Andreas Bäbler,et al. Psilocybin induces schizophrenia‐like psychosis in humans via a serotonin‐2 agonist action , 1998, Neuroreport.
[25] H. Saito,et al. Inhibition by 5‐HT7 receptor stimulation of GABAA receptor‐activated current in cultured rat suprachiasmatic neurones. , 1994, The Journal of physiology.
[26] A. Sleight,et al. 5-HT(6) receptor antagonists: lead optimisation and biological evaluation of N-aryl and N-heteroaryl 4-amino-benzene sulfonamides. , 2001, European journal of medicinal chemistry.
[27] M. J. Burton,et al. SB-216641 and BRL-15572 – compounds to pharmacologically discriminate h5-HT1B and h5-HT1D receptors , 1997, Naunyn-Schmiedeberg's Archives of Pharmacology.
[28] C. Langmead,et al. The effect of SB‐269970, a 5‐HT7 receptor antagonist, on 5‐HT release from serotonergic terminals and cell bodies , 2001, British journal of pharmacology.
[29] Allan Fletcher,et al. Electrophysiological, biochemical, neurohormonal and behavioural studies with WAY-100635, a potent, selective and silent 5-HT1A receptor antagonist , 1995, Behavioural Brain Research.
[30] M. Millan,et al. Induction of hypothermia as a model of 5-hydroxytryptamine1A receptor-mediated activity in the rat: a pharmacological characterization of the actions of novel agonists and antagonists. , 1993, The Journal of pharmacology and experimental therapeutics.
[31] T. Branchek,et al. A subfamily of 5-HT1D receptor genes. , 1992, Trends in pharmacological sciences.
[32] F. Monsma,et al. Determination of the role of the 5-ht6 receptor in the rat brain: a study using antisense oligonucleotides. , 1995, The Journal of pharmacology and experimental therapeutics.
[33] R. Eglen,et al. Peripheral 5‐HT4 receptors , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[34] R. Hen,et al. 5-hydroxytryptamine-moduline, a new endogenous cerebral peptide, controls the serotonergic activity via its specific interaction with 5-hydroxytryptamine1B/1D receptors. , 1996, Molecular pharmacology.
[35] L. D. van de Kar,et al. Selective serotonin reuptake inhibitors and neuroendocrine function. , 1999, Life sciences.
[36] M. Caron,et al. The genomic clone G-21 which resembles a β-adrenergic receptor sequence encodes the 5-HT1A receptor , 1988, Nature.
[37] R. Myers,et al. Primary structure and functional expression of the 5HT3 receptor, a serotonin-gated ion channel. , 1991, Science.
[38] R. Beroukhim,et al. Ultrastructure of the 5‐Hydroxytryptamine3 Receptor , 1995, Journal of neurochemistry.
[39] D. Middlemiss,et al. SB‐224289–a novel selective (human) 5‐HT1B receptor antagonist with negative intrinsic activity , 1998, British journal of pharmacology.
[40] D. Hoyer,et al. Characterization of the 5-HT1B recognition site in rat brain: binding studies with (-)[125I]iodocyanopindolol. , 1985, European journal of pharmacology.
[41] I. Forbes,et al. In vivo properties of SB 200646A, a 5‐HT2C/2B receptor antagonist , 1994, British journal of pharmacology.
[42] H. Kalkman. RU 24969-induced locomotion in rats is mediated by 5-HT1A receptors , 1995, Naunyn-Schmiedeberg's Archives of Pharmacology.
[43] T. Branchek,et al. Characterization of LY344864 as a pharmacological tool to study 5-HT1F receptors: binding affinities, brain penetration and activity in the neurogenic dural inflammation model of migraine. , 1997, Life sciences.
[44] J. Hagan,et al. The selective 5-HT1B receptor inverse agonist 1'-methyl-5-[[2'-methyl-4'-(5-methyl-1,2, 4-oxadiazol-3-yl)biphenyl-4-yl]carbonyl]-2,3,6,7-tetrahydro- spiro[furo[2,3-f]indole-3,4'-piperidine] (SB-224289) potently blocks terminal 5-HT autoreceptor function both in vitro and in vivo. , 1998, Journal of medicinal chemistry.
[45] S. Lightowler,et al. Activation of 5-HT2B Receptors in the Medial Amygdala causes Anxiolysis in the Social Interaction Test in the Rat , 1997, Neuropharmacology.
[46] F. Lezoualc’h,et al. Pharmacological characterization of the human 5‐HT4(d) receptor splice variant stably expressed in Chinese hamster ovary cells , 2000, British journal of pharmacology.
[47] F. Lezoualc’h,et al. Isolation of the serotoninergic 5‐HT4(e) receptor from human heart and comparative analysis of its pharmacological profile in C6‐glial and CHO cell lines , 2000, British journal of pharmacology.
[48] J. Palacios,et al. Localization of 5-HT1B, 5-HT1Dα, 5-HT1E and 5-HT1F receptor messenger RNA in rodent and primate brain , 1994, Neuropharmacology.
[49] M. Chesselet,et al. Increased m-CPP-induced oral dyskinesia after lesion of serotonergic neurons , 2001, Pharmacology Biochemistry and Behavior.
[50] Á. Pazos,et al. Identification and Characterization of a New Serotonergic Recognition Site with High Affinity for 5‐Carboxamidotryptamine in Mammalian Brain , 1997, Journal of neurochemistry.
[51] A. Kjaer,et al. Adrenocorticotropic Hormone Secretion in Rats Induced by Stimulation with Serotonergic Compounds , 1999 .
[52] C. Dourish,et al. 5‐HT2C receptor modulation and the treatment of obesity , 1999, Diabetes, obesity & metabolism.
[53] M. Moskowitz,et al. Effects of PNU-109,291, a selective 5-HT1D receptor agonist, on electrically induced dural plasma extravasation and capsaicin-evoked c-fos immunoreactivity within trigeminal nucleus caudalis , 1999, Neuropharmacology.
[54] C. Sibella-Argüelles. The proliferation of human T lymphoblastic cells induced by 5-HT1B receptors activation is regulated by 5-HT-moduline. , 2001, Comptes rendus de l'Academie des sciences. Serie III, Sciences de la vie.
[55] D. Nelson,et al. Molecular cloning, functional expression, and pharmacological characterization of a novel serotonin receptor (5-hydroxytryptamine2F) from rat stomach fundus. , 1992, Molecular pharmacology.
[56] M. Hamon. Central and peripheral 5-HT3 receptors , 1992 .
[57] D. Storm,et al. Stimulation of Type 1 and Type 8 Ca2+/Calmodulin-sensitive Adenylyl Cyclases by the Gs-coupled 5-Hydroxytryptamine Subtype 5-HT7AReceptor* , 1998, The Journal of Biological Chemistry.
[58] P P Humphrey,et al. 5-Hydroxytryptamine-induced relaxation of isolated mammalian smooth muscle. , 1983, European journal of pharmacology.
[59] D. Middlemiss,et al. SB-236057, a selective 5-HT1B receptor inverse agonist, blocks the 5-HT human terminal autoreceptor. , 1999, European journal of pharmacology.
[60] C. de Montigny,et al. Autoregulatory properties of dorsal raphe 5‐HT neurons: Possible role of electrotonic coupling and 5‐HT1D receptors in the rat brain , 1996, Synapse.
[61] D. Reiss,et al. Characterization of 5-hydroxytryptamine receptors in rat stomach fundus. , 1985, The Journal of pharmacology and experimental therapeutics.
[62] G. Fillion,et al. Autoradiographic characterization of [3H]-5-HT-moduline binding sites in rodent brain and their relationship to 5-HT1B receptors. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[63] J. Fozard,et al. The 5-HT4 receptor: naughty, but nice. , 1989, Trends in pharmacological sciences.
[64] M. Millan,et al. Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a []GTPγS binding study , 1998 .
[65] T. Blackburn,et al. BW 723C86, a 5-HT2B Receptor Agonist, Causes Hyperphagia and Reduced Grooming in Rats , 1997, Neuropharmacology.
[66] E. A. Forster,et al. Direct evidence for an important species difference in the mechanism of 8‐OH‐DPAT‐induced hypothermia , 1991, British journal of pharmacology.
[67] D. Sibley,et al. Cloning, Characterization, and Chromosomal Localization of a Human 5‐HT6 Serotonin Receptor , 1996, Journal of neurochemistry.
[68] J. Palacios,et al. Homogeneous 5-HT1D recognition sites in the human substantia nigra identified with a new iodinated radioligand. , 1991, European journal of pharmacology.
[69] M. Millan,et al. Serotonin (5-HT)2C receptors tonically inhibit dopamine (DA) and noradrenaline (NA), but not 5-HT, release in the frontal cortex in vivo , 1998, Neuropharmacology.
[70] D. Hoyer. Molecular pharmacology and biology of 5-HT1C receptors. , 1988, Trends in pharmacological sciences.
[71] U. Knigge,et al. Differential Effect of Serotonin 5-HT1A Receptor Antagonists on the Secretion of Corticotropin and Prolactin , 2001, Neuroendocrinology.
[72] G. Reynolds,et al. Characterization of [3H]GR 113808 binding to 5-HT4 receptors in brain tissues from patients with neurodegenerative disorders , 1995, Behavioural Brain Research.
[73] C. Marsden,et al. Involvement of 5‐HT2 receptors in the behaviours produced by intrathecal administration of selected 5‐HT agonists and the TRH analogue (CG 3509) to rats , 1989, British journal of pharmacology.
[74] E. Schröck,et al. Assignment of a human homolog of the mouse Htr3 receptor gene to chromosome 11q23.1-q23.2. , 1995, Genomics.
[75] J. Bockaert,et al. Novel brain-specific 5-HT4 receptor splice variants show marked constitutive activity: role of the C-terminal intracellular domain. , 1999, Molecular pharmacology.
[76] D. Hoyer,et al. A proposed new nomenclature for 5-HT receptors. , 1993, Trends in pharmacological sciences.
[77] D. Middlemiss,et al. The 5‐HT1B Receptors , 1990, Annals of the New York Academy of Sciences.
[78] I. Boyd,et al. Urinary disorders associated with cisapride , 1994 .
[79] A. Sleight,et al. Identification of 5-hydroxytryptamine7 receptor binding sites in rat hypothalamus: sensitivity to chronic antidepressant treatment. , 1995, Molecular pharmacology.
[80] B. O'dowd,et al. Oligomerization of Dopamine and Serotonin Receptors , 2000, Neuropsychopharmacology.
[81] H. Kao,et al. The 5‐HT4 receptor: molecular cloning and pharmacological characterization of two splice variants. , 1995, The EMBO journal.
[82] K. Fink,et al. Evidence for presynaptic location of inhibitory 5-HT1D\-like autoreceptors in the guinea-pig brain cortex , 1996, Naunyn-Schmiedeberg's Archives of Pharmacology.
[83] P. Celada,et al. How does pindolol improve antidepressant action? , 2001, Trends in pharmacological sciences.
[84] M. Millan,et al. Potentiation of fluoxetine-induced penile erections by combined blockade of 5-HT1A and 5-HT1B receptors. , 1997, European journal of pharmacology.
[85] R Hen,et al. Enhanced aggressive behavior in mice lacking 5-HT1B receptor. , 1994, Science.
[86] Lynn P. Martin,et al. Electrophysiological comparison of 5-Hydroxytryptamine1A receptor antagonists on dorsal raphe cell firing. , 1999, The Journal of pharmacology and experimental therapeutics.
[87] R. Hen,et al. Elevated alcohol consumption in null mutant mice lacking 5–HT1B serotonin receptors , 1996, Nature Genetics.
[88] R. Clark,et al. Medicinal Chemistry of 5-HT4 Receptor Ligands , 1998 .
[89] T. Branchek,et al. Functional characterization of the recombinant human 5-hydroxytryptamine7(a) receptor isoform coupled to adenylate cyclase stimulation. , 1998, The Journal of pharmacology and experimental therapeutics.
[90] G. Reynolds,et al. 5‐Hydroxytryptamine (5‐HT)4 receptors in post mortem human brain tissue: distribution, pharmacology and effects of neurodegenerative diseases , 1995, British journal of pharmacology.
[91] T. Branchek,et al. A receptor autoradiographic and in situ hybridization analysis of the distribution of the 5‐ht7 receptor in rat brain , 1996, British journal of pharmacology.
[92] R. Eglen,et al. Characterization and distribution of putative 5‐ht7 receptors in guinea‐pig brain , 1995, British journal of pharmacology.
[93] M. Jurzak,et al. Cloning and Expression of a Human Serotonin 5‐HT4 Receptor cDNA , 1997, Journal of neurochemistry.
[94] M. Teitler,et al. Quantitative autoradiography of 5-CT-sensitive (5-HT1D) and 5-CT-insensitive (5-HT1E) serotonin receptors in human brain , 1992, Neuroscience Letters.
[95] G. Martin,et al. Alignment of receptor nomenclature with the human genome: classification of 5-HT1B and 5-HT1D receptor subtypes. , 1996, Trends in pharmacological sciences.
[96] J. Hagan,et al. Characterization of SB‐269970‐A, a selective 5‐HT7 receptor antagonist , 2000, British journal of pharmacology.
[97] D. Middlemiss,et al. Characterization of [125I]‐SB‐258585 binding to human recombinant and native 5‐HT6 receptors in rat, pig and human brain tissue , 2000 .
[98] C. Glass,et al. The Pharmacological and Functional Characteristics of the Serotonin 5-HT3A Receptor Are Specifically Modified by a 5-HT3B Receptor Subunit* , 1999, The Journal of Biological Chemistry.
[99] B. Roth,et al. Evidence for Possible Involvement of 5-HT2B Receptors in the Cardiac Valvulopathy Associated With Fenfluramine and Other Serotonergic Medications , 2000, Circulation.
[100] G. P. Lewis. The inhibition by morphine of the action of smooth muscle stimulants on the guinea-pig intestine. , 1960, British journal of pharmacology and chemotherapy.
[101] M. Jurzak,et al. Structure of the Human Serotonin 5‐HT4 Receptor Gene and Cloning of a Novel 5‐HT4 Splice Variant , 2000, Journal of neurochemistry.
[102] I. Martin,et al. Molecular biology of 5-HT receptors , 1994, Neuropharmacology.
[103] H. Lübbert,et al. Expression of serotonin receptor mRNAs in blood vessels , 1995, FEBS letters.
[104] G. Tunnicliff. Molecular basis of buspirone's anxiolytic action. , 1991, Pharmacology & toxicology.
[105] G. W. Price,et al. Interaction of serotonin autoreceptor antagonists in the rat dorsal raphe nucleus: an in vitro fast cyclic voltammetry study , 2001, Neuroscience Letters.
[106] R. Nicholson,et al. Anesthetic-like Interaction of the Sleep-inducing Lipid Oleamide with Voltage-gated Sodium Channels in Mammalian Brain , 2001, Anesthesiology.
[107] P. Hartig,et al. Messenger RNA Editing of the Human Serotonin 5-HT2C Receptor , 1999, Neuropsychopharmacology.
[108] J. D. den Boer,et al. Serotonergic drugs in the treatment of depressive and anxiety disorders , 2000, Human psychopharmacology.
[109] R. Emeson,et al. Regulation of serotonin-2C receptor G-protein coupling by RNA editing , 1997, Nature.
[110] M. Jurzak,et al. The human 5-ht5A receptor couples to Gi/Go proteins and inhibits adenylate cyclase in HEK 293 cells. , 1998, European journal of pharmacology.
[111] G. Martin,et al. Receptors for 5-Hydroxytryptamine: Current perspectives on classification and nomenclature , 1994, Neuropharmacology.
[112] A. Eison,et al. Effects of Antidepressants on 5-HT7 Receptor Regulation in the Rat Hypothalamus , 1999, Neuropsychopharmacology.
[113] S. Bromidge,et al. Phenyl benzenesulfonamides are novel and selective 5-HT6 antagonists: identification of N-(2,5-dibromo-3-fluorophenyl)-4-methoxy-3-piperazin-1-ylbenzenesulfonamide (SB-357134). , 2001, Bioorganic & medicinal chemistry letters.
[114] D. Cox,et al. 5-HT2B receptor signaling in the rat stomach fundus: dependence on calcium influx, calcium release and protein kinase C , 1995, Behavioural Brain Research.
[115] C. Niswender,et al. Serotonin 5‐HT2C Receptor RNA Editing Alters Receptor Basal Activity , 1999, Journal of neurochemistry.
[116] D. Sibley,et al. Molecular cloning and expression of a 5-hydroxytryptamine7 serotonin receptor subtype. , 1993, The Journal of biological chemistry.
[117] F. Bloom,et al. Psychopharmacology: The Fourth Generation of Progress , 1995 .
[118] P J Lovell,et al. A novel, potent, and selective 5-HT(7) antagonist: (R)-3-(2-(2-(4-methylpiperidin-1-yl)ethyl)pyrrolidine-1-sulfonyl) phen ol (SB-269970). , 2000, Journal of medicinal chemistry.
[119] I. Lucki,et al. Antidepressant-like behavioral effects in 5-hydroxytryptamine(1A) and 5-hydroxytryptamine(1B) receptor mutant mice. , 2001, The Journal of pharmacology and experimental therapeutics.
[120] J. Hagan,et al. The effect of SB-236057-A, a selective 5-HT1B receptor inverse agonist, on in vivo extracellular 5-HT levels in the freely-moving guinea-pig , 2000, Naunyn-Schmiedeberg's Archives of Pharmacology.
[121] J. Hagan,et al. Functional characterisation of the human cloned 5‐HT7 receptor (long form); antagonist profile of SB‐258719 , 1998, British journal of pharmacology.
[122] R. Fischmeister,et al. Molecular and functional characterization of a 5‐HT4 receptor cloned from human atrium , 1997, FEBS letters.
[123] H. Vijverberg,et al. 5-HT3 receptors and neurotransmitter release in the CNS: a nerve ending story? , 2000, Trends in Neurosciences.
[124] T. Branchek,et al. Molecular biology and potential functional role of 5-HT5, 5-HT6, and 5-HT7 receptors , 2000 .
[125] M. Kanje,et al. 5-HT1B and 5-HT1D receptors in the human trigeminal ganglion: co-localization with calcitonin gene-related peptide, substance P and nitric oxide synthase , 2001, Brain Research.
[126] S H Snyder,et al. Multiple serotonin receptors: differential binding of [3H]5-hydroxytryptamine, [3H]lysergic acid diethylamide and [3H]spiroperidol. , 1979, Molecular pharmacology.
[127] D. S. Cowen,et al. 5-HT7 receptors activate the mitogen activated protein kinase extracellular signal related kinase in cultured rat hippocampal neurons , 2001, Neuroscience.
[128] D. Hoyer,et al. Molecular pharmacology of 5-HT1 and 5-HT2 recognition sites in rat and pig brain membranes: radioligand binding studies with [3H]5-HT, [3H]8-OH-DPAT, (-)[125I]iodocyanopindolol, [3H]mesulergine and [3H]ketanserin. , 1985, European journal of pharmacology.
[129] G. Martin,et al. 5-HT Receptor Classification and Nomenclature: Towards a Harmonization with the Human Genome , 1997, Neuropharmacology.
[130] B. Largent,et al. Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine. , 2000, Molecular pharmacology.
[131] M. Tricklebank. The behavioural response to 5-HT receptor agonists and subtypes of the central 5-HT receptor , 1985 .
[132] D. Middlemiss,et al. Pharmacological characterisation of human 5-HT2 receptor subtypes. , 2001, European journal of pharmacology.
[133] B. O'dowd,et al. Serotonin 5‐HT1B and 5‐HT1D receptors form homodimers when expressed alone and heterodimers when co‐expressed , 1999, FEBS letters.
[134] R M Eglen,et al. Electrophysiological and antiarrhythmic effects of the atrial selective 5-HT(4) receptor antagonist RS-100302 in experimental atrial flutter and fibrillation. , 1999, Circulation.
[135] I. Forbes,et al. In vitro and in vivo profile of SB 206553, a potent 5‐HT2C/5‐HT2B receptor antagonist with anxiolytic‐like properties , 1996, British journal of pharmacology.
[136] I. Lucki. 5-HT1 receptors and behavior , 1992, Neuroscience & Biobehavioral Reviews.
[137] M. Hamon,et al. Developmental Changes in the Differential Expression of Two Serotonin 5‐HT3 Receptor Splice Variants in the Rat , 1995, Journal of neurochemistry.
[138] T. Blackburn,et al. Evidence for expression of the 5-hydroxytryptamine-2B receptor protein in the rat central nervous system , 1997, Neuroscience.
[139] T. Shinkai,et al. Novel polymorphism in the 5′-upstream region of the human 5-HT6 receptor gene and schizophrenia , 2001, Neuroscience Letters.
[140] M. Piercey,et al. Characterization of U-92016A as a selective, orally active, high intrinsic activity 5-hydroxytryptamine1A agonist. , 1994, The Journal of pharmacology and experimental therapeutics.
[141] J. Schwartz,et al. Molecular cloning, characterization, and localization of a high-affinity serotonin receptor (5-HT7) activating cAMP formation. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[142] G. Fillion,et al. Immunocytochemical localization of neurons expressing 5-HT-moduline in the mouse brain , 1997, Neuropharmacology.
[143] D. Middlemiss,et al. Characterization of SB‐271046: A potent, selective and orally active 5‐HT6 receptor antagonist , 2000, British journal of pharmacology.
[144] P. Barone,et al. Quantitative autoradiography of 5-HT1E binding sites in rodent brains: effect of lesion of serotonergic neurones. , 1993, European journal of pharmacology.
[145] P. Barone,et al. Quantitative autoradiography of 5-HT1D and 5-HT1E binding sites labelled by [3H]5-HT, in frontal cortex and the hippocampal region of the human brain , 1994, Brain Research.
[146] J. Crabbe,et al. Genetics of mouse behavior: interactions with laboratory environment. , 1999, Science.
[147] Colleen M Niswender,et al. RNA Editing of the Human Serotonin 5-HT2C Receptor: Alterations in Suicide and Implications for Serotonergic Pharmacotherapy , 2001, Neuropsychopharmacology.
[148] S. Snyder,et al. Serotonin and lysergic acid diethylamide binding in rat brain membranes: relationship to postsynaptic serotonin receptors. , 1976, Molecular pharmacology.
[149] N. Barnes,et al. Neurochemical Consequences Following Pharmacological Manipulation of Central 5-HT4 Receptors , 1998 .
[150] J. Hagan,et al. [3H]‐SB‐269970 – A selective antagonist radioligand for 5‐HT7 receptors , 2000 .
[151] B. Roth,et al. 2-Substituted tryptamines: agents with selectivity for 5-HT(6) serotonin receptors. , 2000, Journal of medicinal chemistry.
[152] T. Gray,et al. 5-HT2A Receptors Stimulate ACTH, Corticosterone, Oxytocin, Renin, and Prolactin Release and Activate Hypothalamic CRF and Oxytocin-Expressing Cells , 2001, The Journal of Neuroscience.
[153] R. Fischmeister,et al. Cloning, Expression, and Pharmacology of Four Human 5‐Hydroxytryptamine4 Receptor Isoforms Produced by Alternative Splicing in the Carboxyl Terminus , 1998, Journal of neurochemistry.
[154] A. Sleight,et al. A role for 5-ht6 receptors in retention of spatial learning in the Morris water maze , 2001, Neuropharmacology.
[155] P B Hedlund,et al. Allosteric regulation by oleamide of the binding properties of 5-hydroxytryptamine7 receptors. , 1999, Biochemical pharmacology.
[156] M. Bourin,et al. 5-HT-moduline, a 5-HT(1B/1D) receptor endogenous modulator, interacts with dopamine release measured in vivo by microdialysis. , 1998, European journal of pharmacology.
[157] D. Middlemiss,et al. Species differences in the pharmacology of terminal 5-HT autoreceptors in mammalian brain. , 1989, Trends in pharmacological sciences.
[158] B. O'dowd,et al. Oligomerization of mu- and delta-opioid receptors. Generation of novel functional properties. , 2000, The Journal of biological chemistry.
[159] J. Vane,et al. An analysis of the direct and indirect actions of drugs on the isolated guinea-pig ileum. , 1963, British journal of pharmacology and chemotherapy.
[160] J. Sutcliffe,et al. Oleamide‐induced Modulation of 5‐Hydroxytryptamine Receptor‐mediated Signaling a , 1998, Annals of the New York Academy of Sciences.
[161] B. Sacks,et al. Eltoprazine in aggressive mentally handicapped patients: a double‐blind, placebo- and baseline‐controlled multi‐centre study , 1994, International clinical psychopharmacology.
[162] M. Cohen,et al. Contractile serotonergic receptor in rat stomach fundus. , 1987, The Journal of pharmacology and experimental therapeutics.
[163] I A Cliffe,et al. A pharmacological profile of the selective silent 5-HT1A receptor antagonist, WAY-100635. , 1995, European journal of pharmacology.
[164] T. Branchek,et al. Cloning of a novel human serotonin receptor (5-HT7) positively linked to adenylate cyclase. , 1993, The Journal of biological chemistry.
[165] R. Kohen,et al. Four 5‐Hydroxytryptamine7 (5‐HT7) Receptor Isoforms in Human and Rat Produced by Alternative Splicing: Species Differences Due to Altered Intron‐Exon Organization , 1997, Journal of neurochemistry.
[166] A. Meneses. Effects of the 5-HT6 receptor antagonist Ro 04-6790 on learning consolidation , 2001, Behavioural Brain Research.
[167] J. Seckl,et al. Acute restraint stress increases 5-HT7 receptor mRNA expression in the rat hippocampus , 2001, Neuroscience Letters.
[168] A. Sleight,et al. 5-HT2C receptor agonists: pharmacological characteristics and therapeutic potential. , 1998, The Journal of pharmacology and experimental therapeutics.
[169] R. Eglen,et al. Characterization of a postjunctional 5-HT receptor mediating relaxation of guinea-pig isolated ileum. , 1995, European journal of pharmacology.
[170] M. Hamon,et al. [Role of serotonin and other neuroactive molecules in the physiopathogenesis of migraine. Current hypotheses]. , 2000, Pathologie-biologie.
[171] J. C. Winter,et al. The interactions of typical and atypical antipsychotics with the (−)2,5,-dimethoxy-4-methamphetamine (DOM) discriminative stimulus , 1995, Neuropharmacology.
[172] G. Aghajanian,et al. Serotonin and Hallucinogens , 1999, Neuropsychopharmacology.
[173] H. Boddeke,et al. 5‐HT2B receptor‐mediated calcium release from ryanodine‐sensitive intracellular stores in human pulmonary artery endothelial cells , 1996, British journal of pharmacology.
[174] D. Middlemiss,et al. Effects of selective h5-HT1B (SB-216641) and h5-HT1D (BRL-15572) receptor ligands on guinea-pig and human 5-HT auto- and heteroreceptors , 1997, Naunyn-Schmiedeberg's Archives of Pharmacology.
[175] G. Fillion,et al. 5-Hydroxytryptamine-moduline: a novel endogenous peptide involved in the control of anxiety , 1999, Neuroscience.
[176] S. Cheetham,et al. Evidence that RU 24969‐induced locomotor activity in C57/B1/6 mice is specifically mediated by the 5‐HT1B receptor , 1993, British journal of pharmacology.
[177] P. Szot,et al. Function and distribution of three rat 5-hydroxytryptamine7 (5-HT7) receptor isoforms produced by alternative splicing , 1998, Neuropharmacology.
[178] R. Eglen,et al. Cloning, expression and pharmacology of a truncated splice variant of the human 5‐HT7 receptor (h5‐HT7(b)) , 1997 .
[179] S. Watts,et al. Characterization of the serotonin receptor mediating contraction in the mouse thoracic aorta and signal pathway coupling. , 2001, The Journal of pharmacology and experimental therapeutics.
[180] M. Erlander,et al. Two members of a distinct subfamily of 5-hydroxytryptamine receptors differentially expressed in rat brain. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[181] L H Parsons,et al. Elevated anxiety and antidepressant-like responses in serotonin 5-HT1A receptor mutant mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[182] J. Leysen,et al. Alniditan, a new 5-hydroxytryptamine1D agonist and migraine-abortive agent: ligand-binding properties of human 5-hydroxytryptamine1D alpha, human 5-hydroxytryptamine1D beta, and calf 5-hydroxytryptamine1D receptors investigated with [3H]5-hydroxytryptamine and [3H]alniditan. , 1996, Molecular pharmacology.
[183] R Hen,et al. Regional changes in density of serotonin transporter in the brain of 5‐HT1A and 5‐HT1B knockout mice, and of serotonin innervation in the 5‐HT1B knockout , 2001, Journal of neurochemistry.
[184] J. A. Peters,et al. Cloning and functional expression of an apparent splice variant of the murine 5-HT3 receptor A subunit. , 1993, European journal of pharmacology.
[185] L. Sanders,et al. 5-Hydroxytryptamine causes rate-dependent arrhythmias through 5-HT4 receptors in human atrium: facilitation by chronic β-adrenoceptor blockade , 1994, Naunyn-Schmiedeberg’s Archives of Pharmacology.
[186] W. Feniuk,et al. 5-Carboxamidotryptamine: a potent agonist mediating relaxation and elevation of cyclic AMP in the isolated neonatal porcine vena cava. , 1986, Life sciences.
[187] M Toth,et al. Increased anxiety of mice lacking the serotonin1A receptor. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[188] R. Schreiber,et al. (1-(2,5-dimethoxy-4 iodophenyl)-2-aminopropane)-induced head-twitches in the rat are mediated by 5-hydroxytryptamine (5-HT) 2A receptors: modulation by novel 5-HT2A/2C antagonists, D1 antagonists and 5-HT1A agonists. , 1995, The Journal of pharmacology and experimental therapeutics.
[189] C. Davies,et al. SB‐272183, a selective 5‐HT1A, 5‐HT1B and 5‐HT1D receptor antagonist in native tissue , 2001, British journal of pharmacology.
[190] J. Palacios,et al. Characterization of human serotonin 1D and 1B receptors using [ 3H]-GR-125743, a novel radiolabelled serotonin 5HT1D/1B receptor antagonist , 1997, Naunyn-Schmiedeberg's Archives of Pharmacology.
[191] N. Barnes,et al. Allosteric modulation of 5-HT3 receptors: focus on alcohols and anaesthetic agents. , 1996, Trends in pharmacological sciences.
[192] F. O. Risinger,et al. Oral operant ethanol self-administration in 5-HT1b knockout mice , 1999, Behavioural Brain Research.
[193] J. Sutcliffe,et al. The Endogenous Lipid Oleamide Activates Serotonin 5‐HT7 Neurons in Mouse Thalamus and Hypothalamus , 1999, Journal of neurochemistry.
[194] P. Bradley,et al. Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine , 1986, Neuropharmacology.
[195] M. Cohen,et al. Further evidence that the serotonin receptor in the rat stomach fundus is not 5HT1A or 5HT1B. , 1986, Life sciences.
[196] R. Eglen. 5-Hydroxytryptamine (5-HT)4 receptors and central nervous system function: an update. , 1997, Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques.
[197] P. Pauwels. 5-HT 1B/D receptor antagonists. , 1997, General pharmacology.
[198] E. Zifa,et al. A new peptide, 5-HT-moduline, isolated and purified from mammalian brain specifically interacts with 5-HT 1B 1D receptors , 1995, Behavioural Brain Research.
[199] D. Sibley,et al. Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. , 1994, The Journal of pharmacology and experimental therapeutics.
[200] M. Neal,et al. Unique allosteric regulation of 5-hydroxytryptamine receptor-mediated signal transduction by oleamide. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[201] P P Humphrey,et al. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). , 1994, Pharmacological reviews.
[202] J. Bockaert,et al. 5-HT6 receptors positively coupled to adenylyl cyclase in striatal neurones in culture. , 1994, Neuroreport.
[203] G. Fillion,et al. Acute stress induces a differential increase of 5-HT-moduline (LSAL) tissue content in various rat brain areas , 1999, Brain Research.
[204] Colleen M. Niswender,et al. RNA Editing of the Human Serotonin 5-Hydroxytryptamine 2C Receptor Silences Constitutive Activity* , 1999, The Journal of Biological Chemistry.
[205] Kirk W. Johnson,et al. 5‐HT1F receptor agonists inhibit neurogenic dural inflammation in guinea pigs , 1997, Neuroreport.
[206] M. Millan,et al. 5-HT2C receptors mediate penile erections in rats: actions of novel and selective agonists and antagonists. , 1997, European journal of pharmacology.
[207] A. Brown,et al. SB 242084, a Selective and Brain Penetrant 5-HT2C Receptor Antagonist , 1997, Neuropharmacology.
[208] G. Fillion,et al. Mapping of 5-HT-moduline binding sites in guinea-pig brain by film and digital autoradiography , 1998, Brain Research.
[209] C. Waeber,et al. [3H]sumatriptan labels both 5-HT1D and 5-HT1F receptor binding sites in the guinea pig brain: an autoradiographic study , 1995, Naunyn-Schmiedeberg's Archives of Pharmacology.
[210] J. Stamford,et al. Multiple 5-HT1 autoreceptor subtypes govern serotonin release in dorsal and median raphé nuclei , 2001, Neuropharmacology.
[211] J. Bockaert,et al. Cloning and expression of human 5‐HT4S receptors. Effect of receptor density on their coupling to adenylyl cyclase , 1997, Neuroreport.
[212] T. Mansour,et al. Serotonin receptor-mediated activation of adenylate cyclase in the neuroblastoma NCB.20: a novel 5-hydroxytryptamine receptor. , 1990, Molecular pharmacology.
[213] D. Hoyer. Serotonin 5-HT3, 5-HT4, and 5-HT-M receptors. , 1990, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.
[214] G. Kennett,et al. Evidence that hypophagia induced by d-fenfluramine and d-norfenfluramine in the rat is mediated by 5-HT2C receptors , 2001, Neuropharmacology.
[215] M. Buhot,et al. 5-HT1B receptor knock out — behavioral consequences , 1995, Behavioural Brain Research.
[216] M. Gershon. Review article: roles played by 5‐hydroxytryptamine in the physiology of the bowel , 1999, Alimentary pharmacology & therapeutics.
[217] B. O'dowd,et al. Orphan G protein-coupled receptors in the CNS. , 2001, Current opinion in pharmacology.
[218] K. Simansky. Serotonin and the Structure of Satiation , 1998 .